Study S001086

Efficacy and Safety of Tirzepatide Once Weekly in Chinese Participants Without Type 2 Diabetes Who Have Obesity or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind, Placebo-Controlled Trial (SURMOUNT-CN)

Included trial: extracted data ClinicalTrials.gov record Study Protocol (PDF)Statistical Analysis Plan (PDF)

Registration

Registration: NCT05024032
Acronym: SURMOUNT-CN
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 210
Start: 2021-09-01
Primary completion: 2022-12-27
Lead sponsor: Eli Lilly and Company
Conditions: Obesity; Overweight; Metabolism and Nutrition Disorder
Interventions: DRUG:Tirzepatide; DRUG:Placebo
Results posted: TRUE
Individual participant data sharing: YES
Secondary identifiers: OTHER:I8F-MC-GPIA

Registered primary outcomes

Mean Percent Change From Baseline in Body Weight [Baseline, Week 52]
Percentage of Participants Who Achieve ≥5% Body Weight Reduction [Week 52]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0016998	Achieving BMI <25 kg/m2 was associated with reduced predicted risk of atherosclerotic cardiovascular disease in people with obesity or overweight on tirzepatide or placebo: a post hoc analysis of SURMOUNT-1, -3, and -CN. Guo L, EClinicalMedicine	2026	Randomized trial	PMID 41536939 DOI	cites ClinicalTrials.gov:NCT05024032
R0007857	Weight loss maintenance after tirzepatide cessation in people with overweight/obesity: a real-world follow-up of the phase 3 SURMOUNT-CN trial. Chen C, Life metabolism	2025	Nonrandomized study	PMID 42058132 DOI	cites ClinicalTrials.gov:NCT05024032
R0049852	1729-P: Achieving BMI <25 kg/m2 Was Associated with Reduced Predicted Risk of Atherosclerotic Cardiovascular Disease in People with Obesity or Overweight—A Post Hoc Analysis of SURMOUNT-1, -3, and -CN Lixin Guo, Diabetes	2025	Randomized trial	DOI	cites ClinicalTrials.gov:NCT05024032
R0018279	Tirzepatide for Weight Reduction in Chinese Adults With Obesity: The SURMOUNT-CN Randomized Clinical Trial. Zhao L, JAMA	2024	Randomized trial	PMID 38819983 DOI	cites ClinicalTrials.gov:NCT05024032; registry reference DERIVED:38819983